Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06311708 · ClinicalTrials.gov registry record

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

A clinical trial of Arrhythmogenic Right Ventricular Cardiomyopathy, sponsored by Tenaya Therapeutics.

Recruiting
Registry status
200
Enrollment target
20
Study locations

NCT06311708: Recruiting study of Arrhythmogenic Right Ventricular Cardiomyopathy, sponsored by Tenaya Therapeutics.

NCT06311708 is a study of Arrhythmogenic Right Ventricular Cardiomyopathy that is actively recruiting participants, run by Tenaya Therapeutics. The registered enrollment target is 200 participants, below the 334-participant average among 4 other Arrhythmogenic Right Ventricular Cardiomyopathy trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06311708, a study of Arrhythmogenic Right Ventricular Cardiomyopathy, is actively recruiting participants, sponsored by Tenaya Therapeutics.

RECRUITING
Registry status
200 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.

Study Locations (20)

Other

  • Hopital Louis Pradel - Bron
  • Nantes University Hospital - Nantes
  • Pitié-Salpêtrière Hospital - Paris
  • Hôpital Haut-Lévêque - Pessac
  • University Hospital Muenster - Münster
  • Wuerzburg University Hospital - Würzburg
  • Centro Cardiologico Monzino - Milan
  • Istituti Clinici Scientifici Maugeri SpA - Pavia
  • Skåne University Hospital - Malmo
  • The Queen Elizabeth Hospital - Glasgow
  • Barts & The London Health NHS Trust - London
  • St. George's University Hospitals NHS Foundation Trust - London

California

  • University of California San Francisco - San Francisco

Colorado

  • University of Colorado, Denver - Aurora

Maryland

  • John Hopkins University School of Medicine - Baltimore

Massachusetts

  • Brigham and Women's Hospital - Boston

Minnesota

  • Mayo Clinic - Rochester

New York

  • New York University - New York

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2023-01-31
Est. Completion 2030-07-11
Tenaya Therapeutics

4 total trials

What NCT06311708 shows while recruiting

NCT06311708 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 334-participant average among 4 other Arrhythmogenic Right Ventricular Cardiomyopathy trials with a reported enrollment target (40% lower).

The record links to 1 condition, with Arrhythmogenic Right Ventricular Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.

NCT06311708 names 20 study sites across 9 states, led by Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06311708 about?

NCT06311708 is a clinical study titled "Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)". This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless ...

What is the current status of trial NCT06311708?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-01-31. Estimated completion is 2030-07-11.

What conditions does trial NCT06311708 study?

This clinical trial studies the following conditions: Arrhythmogenic Right Ventricular Cardiomyopathy.

Who is sponsoring clinical trial NCT06311708?

This trial is sponsored by Tenaya Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06311708 being conducted?

This trial has 20 study locations across California, Colorado, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arrhythmogenic Right Ventricular Cardiomyopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06311708, the US trial registry maintained by the National Library of Medicine. NCT06311708 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.